The class of chemicals known as SLC7A12 activators encompasses a diverse range of compounds that can upregulate the function of the SLC7A12 transporter protein. These activators are not a homogenous group but are instead characterized by their ability to engage with various cellular signaling pathways, ultimately influencing the activity of SLC7A12. The primary mechanism through which these activators operate involves the modulation of intracellular pathways that govern the expression, trafficking, and function of this transporter. This can include the activation of protein kinases, which phosphorylate target proteins, thereby altering their activity, or the modulation of gene expression, which adjusts the protein levels within the cell.
SLC7A12 activators can act by stimulating the PI3K/Akt pathway or the AMPK pathway, both of which are involved in cellular energy balance and can lead to changes in the membrane expression of transport proteins. Some activators work by influencing the action of protein kinase C (PKC) or protein kinase A (PKA), which can phosphorylate transporter proteins, changing their conformation and activity. Others can affect gene expression through the action of transcription factors or by altering the epigenetic status of the genes encoding the SLC7A12 transporter. This can result in increased synthesis of the transporter protein and its subsequent insertion into the cell membrane, enhancing the transport capacity for cationic amino acids. Through these methods, SLC7A12 activators can have a significant impact on the regulation of amino acid homeostasis and cellular function, as the proper function of SLC7A12 is essential for the uptake of specific amino acids that are critical for various metabolic processes within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates the PI3K/Akt pathway, which can lead to increased membrane trafficking of transport proteins and could possibly activate SLC7A12. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates PKC, which can phosphorylate and regulate transporter proteins, altering their activity, which could possibly activate SLC7A12. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid regulates gene expression, which may alter the expression levels of amino acid transporters, potentially activating SLC7A12. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which might modulate the activity and expression of transport proteins through energy balance, potentially activating SLC7A12. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium influences GSK-3β activity, which could affect the expression and function of amino acid transporters, potentially activating SLC7A12. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate acts as a histone deacetylase inhibitor, which can lead to changes in gene expression of transporters, potentially activating SLC7A12. | ||||||
D-Cycloserine | 68-41-7 | sc-221470 sc-221470A sc-221470B sc-221470C | 200 mg 1 g 5 g 25 g | $28.00 $77.00 $142.00 $530.00 | 4 | |
d-Cycloserine may act on the system y+ transporter, potentially influencing its activity through competitive inhibition, which could upregulate transporter expression as a compensatory mechanism, possibly activating SLC7A12. | ||||||